JAK2 and myeloproliferative disorder: It was approved for the treatment of myelofibrosis (a myeloproliferative neoplasm), polycythemia vera, and bone marrow cancer in 2011 by the FDA.315 The recently approved fedratinib is a selective JAK2 inhibitor and is used for myelofibrosis treatment in the clinic.316 Meanwhile, it has been reported that fedratinib also showed efficacy in the treatment of NSCLC in preclinical studies.